Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
Status:
Completed
Trial end date:
2017-11-09
Target enrollment:
Participant gender:
Summary
This study looks at what effects (good and bad) a drug called PXD-101 (belinostat) in
combination with the radioactive drug Zevalin (yttrium Y 90 ibritumomab tiuxetan) has on
patients with relapsed aggressive (high-risk) non-Hodgkin lymphoma. Studies in the laboratory
suggest that drugs such as PXD101 can act upon specific cancer cell processes to cause either
death of the cancer cells or prevention of their growth. In human studies with a small number
of patients with this lymphoma, PXD-101 has shown the ability to shrink and slow tumor
growth. When Zevalin is delivered directly to the tumor, the lymphoma cells are destroyed and
this may result in the disappearance of the tumor (remission)